Alcoholic Hepatitis

Detailed Overview

It represents a critical juncture in alcohol-associated liver disease. The metabolism of alcohol in the liver generates toxic byproducts (like acetaldehyde) and reactive oxygen species, which induce intense oxidative stress, lipid peroxidation, and a profound localized inflammatory cascade. This results in ballooning degeneration of hepatocytes, infiltration of polymorphonuclear neutrophils (PMNs), and Mallory-Denk body formation. Severe alcoholic hepatitis has a high short-term mortality rate (up to 30-50% at 1 month without treatment) due to liver failure, portal hypertension complications, and an extremely high susceptibility to bacterial infections.

Epidemiology & Demographics

Occurs in approximately 10-35% of heavy drinkers. The mean age of presentation is 40-50 years. While more total cases occur in men, women are at higher risk for developing the condition at lower doses of alcohol.

Etiological Mechanism

The direct cause is chronic, heavy alcohol consumption. The threshold is typically considered > 80g/day of ethanol for men and > 50g/day for women for at least 5 years, often with a recent period of increased consumption (a "binge").

Primary Causes

Heavy, sustained ethanol consumption

Genetic predisposition (e.g., PNPLA3 gene variants)

Co-existing liver disease (e.g., Hepatitis C, obesity) exacerbates injury

• Amount and duration of alcohol use: The most significant determinant of risk.
• Female Sex: Women have lower gastric alcohol dehydrogenase activity, leading to higher blood alcohol levels for a given dose.
• Malnutrition: Depletes glutathione stores, reducing the liver's ability to neutralize oxidative stress.

1. Ethanol is metabolized by alcohol dehydrogenase to acetaldehyde (highly toxic) and then by ALDH to acetate. 2. Heavy use upregulates CYP2E1, which metabolizes alcohol but generates massive amounts of Reactive Oxygen Species (ROS). 3. Acetaldehyde binds cellular proteins forming neoantigens, triggering an immune response. 4. ROS cause lipid peroxidation and mitochondrial damage. 5. Damaged hepatocytes release damage-associated molecular patterns (DAMPs), and increased gut permeability allows endotoxins (LPS) into the portal vein. 6. LPS activates Kupffer cells via TLR4 to release massive amounts of TNF-alpha and IL-8. 7. This causes dense neutrophil infiltration, severe lobular inflammation, hepatocyte necrosis, and acute loss of synthetic liver function.

Characteristic Clinical Presentation

• Rapid-Onset Jaundice: Yellowing of skin and sclera due to severe hyperbilirubinemia.
• Anorexia and Nausea: Profound loss of appetite, often accompanied by vomiting and severe malnutrition.
• Low-grade Fever: Present in 50% of cases due to the intense inflammatory state (even without infection).
• Right Upper Quadrant Pain: Hepatic swelling stretching Glisson's capsule.

Physical Examination Signs

• Tender Hepatomegaly
• Hepatic Encephalopathy
• Stigmata of Chronic Liver Disease

• Infections: Pneumonia, UTI, and Spontaneous Bacterial Peritonitis (SBP) are extremely common and often fatal due to immune paresis.
• Hepatorenal Syndrome (HRS): Functional renal failure driven by extreme splanchnic vasodilation.
• Variceal Hemorrhage: Acute bleeding from esophageal varices due to rapid worsening of portal hypertension.

Diagnostic Criteria & Guidelines

Clinical diagnosis based on history of heavy alcohol use, recent onset of jaundice, AST > 50 but < 400 IU/L, AST:ALT ratio > 2, and serum bilirubin > 3.0 mg/dL. Liver biopsy is gold standard but reserved for cases with diagnostic uncertainty.

Differential Diagnosis

• Acute Viral Hepatitis (A, B, or E)
• Drug-Induced Liver Injury (e.g., Acetaminophen toxicity)
• Autoimmune Hepatitis
• Biliary Obstruction (Choledocholithiasis)

Laboratory Tests & Biomarkers

• AST and ALT: AST is elevated (typically 100-300 U/L) but rarely >400 U/L. The AST/ALT ratio is typically > 2:1.
• Total Bilirubin: Significantly elevated, usually > 5 mg/dL and rapidly rising.
• Prothrombin Time (PT) / INR: Prolonged, reflecting severely impaired hepatic synthetic function.
• WBC Count: Neutrophilic leukocytosis is common even without infection.

Imaging Modalities & Findings

• Abdominal Ultrasound: Echogenic liver (steatosis), hepatomegaly, reversal of portal vein flow, and ascites. Mainly used to rule out biliary obstruction and hepatocellular carcinoma.

• Mild/Moderate
  Maddrey's Discriminant Function (mDF) < 32. Lower risk of short-term mortality.
• Severe
  mDF ≥ 32 or presence of hepatic encephalopathy. High short-term mortality requiring specific pharmacotherapy.

Second-Line & Adjunctive Therapy

If steroids are contraindicated (e.g., active sepsis, GI bleeding, renal failure), Pentoxifylline 400 mg PO TID was historically used, but recent evidence shows limited efficacy. Early Liver Transplantation is increasingly considered for highly selected patients facing imminent death despite medical therapy.

Surgical & Procedural Management

Liver transplantation is the only definitive cure for failing livers, historically requiring a 6-month abstinence period, but recent protocols allow early transplant in highly selected patients with first-episode severe AH and strong psychosocial support.

Recommended Lifestyle Changes

• Absolute, lifelong abstinence from alcohol.
• Enrollment in alcohol use disorder treatment programs (CBT, AA).
• High-protein, high-calorie diet with daily multivitamin, thiamine, and folate supplementation.

Patient Counseling & Advice

Inform the patient that continuing to drink alcohol is almost certainly fatal. Provide resources for addiction medicine. Explain that steroids may help short-term survival but abstinence is the only long-term cure.

Follow-Up & Monitoring Schedule

Close inpatient monitoring for infections and renal failure. Outpatient follow-up requires monitoring of liver function tests and management of underlying cirrhosis complications (varices screening, HCC surveillance).

Preventive Strategies

Avoid heavy, prolonged alcohol use. Identify and treat alcohol use disorder early.

Poor for severe cases. The 28-day mortality for severe alcoholic hepatitis (mDF ≥ 32) is approximately 30-50%. Long-term survival relies entirely on sustained abstinence; if the patient continues drinking, 5-year survival is <30%.